Animal Health Product Pipeline

Product Pipeline
We are developing a pipeline of prescription drug product candidates and non-prescription products to address unmet needs in animal health.

Canalevia™ is our lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Jaguar has received Minor Use in a Major Species (MUMS) designation for Canalevia for Chemotherapy-Induced Diarrhea (CID) in dogs.

NeonormCalf is our non-prescription product to help dairies and beef farms proactively retain fluid in calves—helping the animals avoid debilitating, dangerous levels of dehydration (learn more). Neonorm is a botanical extract derived from the Croton lechleri tree.

Our product pipeline leverages the data and knowledge our team has gained during the development from human therapeutics into veterinary applications.

Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals.

MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information